Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Immune checkpoint inhibitors produce impressive clinical benefits in cancer types previously considered untreatable, such as metastatic melanoma. However, only some patients benefit from the treatment, for reasons that remain largely unknown. By conducting a large reanalysis of bulk and single-cell RNA sequencing data we uncovered that a specific population of FDCSP+ fibroblasts might predict response to cancer immunotherapy independently of T cells, B cells or tumour mutational burden, thus opening new avenues to explain why some patients do not respond to immune checkpoint inhibitors.
